HGHGrowth Hormone
Human growth hormone (somatropin), a 191-amino-acid protein; reference entry for the calculators, not tracked for price.
Reference compound, not sold here. Profile for research context only.
Overview
Human growth hormone (somatropin) is a 191-amino-acid, ~22 kDa protein hormone made by the anterior pituitary and, since 1985, manufactured recombinantly in E. coli with a sequence identical to the native hormone. It is an FDA-approved prescription biologic, not a research compound: labeled for growth failure from GH deficiency and several genetic short-stature syndromes in children, for adult GH deficiency, and (Serostim) for HIV-associated wasting. The compounds this site tracks for "GH" purposes — sermorelin, ipamorelin, CJC-1295, tesamorelin, MK-677 — are secretagogues that nudge the pituitary; somatropin is the hormone itself. This profile reports what the labels and literature say; it is not dosing or treatment advice.
How it works
Somatropin binds the growth hormone receptor, a class-1 cytokine receptor, dimerising it and activating JAK2/STAT5 signalling. The dominant downstream effect is hepatic and local production of IGF-1, which mediates longitudinal bone growth before epiphyseal closure and most anabolic effects; GH also acts directly to increase lipolysis, reduce insulin sensitivity, raise protein synthesis and promote sodium and water retention. The plasma half-life is short — about 3 h after subcutaneous dosing — but IGF-1 levels respond over days, which is why prescribers titrate to IGF-1 rather than to GH itself. These are human pharmacology findings from the labels, not extrapolations from animal work.
Evidence
Somatropin has decades of human data behind each labeled indication. In the Genotropin adult-GHD trials, six months of treatment increased lean body mass, total body water and the lean-to-fat ratio versus placebo while reducing total body fat and waist circumference; bone mineral density dipped at 6 months and recovered by 12. Pediatric trials established height velocity gains in GH deficiency, Turner syndrome, Prader-Willi syndrome, SHOX deficiency, idiopathic short stature and small-for-gestational-age children, and Serostim trials showed gains in lean mass and body weight in HIV wasting. What the evidence does not support is use in GH-sufficient adults for anti-aging, fat loss or athletic performance — none of these is a labeled indication, and WADA bans GH at all times.
Anecdotal reports community-reported
What people describe in forums, blogs and uncontrolled clinic write-ups — experiential and unverified, not clinical evidence and not medical advice.
- Reported doses people usecommonly reported
Users describe two clusters: sleep, recovery and anti-aging use at 1–3 IU a day (2 IU the most cited, 0.5–1 IU suggested for older users, clinic scripts often 2 IU five days on, two off), and bodybuilding use at 4–10 IU a day, often split morning and evening. Higher daily doses are reported only on heavy stacks and are tied to carpal tunnel and water retention; most say it takes months to judge.
- Sleep: deeper for most, wired nights for somecommonly reported
Deeper sleep is the first thing users credit, several saying they have not slept so well since their teens on 2–3 IU before bed. A sizeable minority get the opposite: a wired, cortisol-like night and almost no sleep from an evening shot, which usually resolves by moving the dose to the morning, fasted, or splitting it. Some say the sleep benefit faded after two to three months.
- Recovery, fullness, skin and hair; little direct sizecommonly reported
Experienced users describe HGH as a background drug: faster recovery, less soreness, fuller muscles while cutting, better joints, thicker hair and skin that 'glows', with fat loss as a bonus rather than direct size. Most say it needs months and a testosterone base to show. A few found 2–6 IU 'nothing to write home about' or quit after four months of hand cramps and weight gain.
- Water retention, numb hands and carpal tunnelcommonly reported
Swollen hands, numb fingers at night and outright carpal tunnel are the most common complaints, usually after starting at 4–5 IU or titrating fast; a few get it even at 2 IU. The usual fix is dropping to 1–2 IU, or stopping for a week or two, then climbing slowly, with relief taking two to three weeks as fluid clears. Potassium, less sodium and split doses are mentioned; one user tolerates 17 IU but not 20.
- Blood sugar: feared more than seena sizeable minority
Insulin resistance is the worry users raise most before starting, yet most who check fasted glucose on 3–4 IU say it stays normal; one reports slightly raised fasted glucose on 3 IU daily that cleared on 5 on / 2 off. Many run retatrutide, berberine, metformin or an SGLT2 inhibitor alongside as insurance and dose fasted or away from carbs. Several warn that 6+ IU daily with high carbs is where trouble starts.
- Grey-market quality: real but variably dosedcommonly reported
Users assume generic HGH is usually real but variably dosed, and treat lab tests and group buys as the only proof; cap colour means nothing. Rules of thumb are an IGF-1 draw after four weeks (one goes from about 200 to 450 on 3 IU), a serum GH test a few hours after a large dose, or cheap test strips. One user on 2 IU for two months saw IGF-1 of 159 and concluded the vials were bunk, or that 2 IU is only replacement.
- Skepticism, acne and tendon flare-upsa sizeable minority
A vocal minority call the benefits placebo plus water: trials in healthy adults show little beyond lean-mass changes, and 'the only way people confirm it is real is numb hands'. Users also report cystic acne that cleared on stopping or dropping from 4 to 2.5 IU, tendinitis flaring when the dose rose to 3 IU and easing within 48 hours of stopping, daytime grogginess in the first weeks, and a puffier face.
Safety
For approved use under specialist monitoring the profile is well characterised. The most common adverse reactions in adults are fluid-retention symptoms — peripheral swelling, arthralgia, extremity pain, paresthesia and stiffness — plus carpal-tunnel-type symptoms; also reported are impaired glucose tolerance and diabetes, intracranial hypertension (usually within the first 8 weeks), unmasked hypothyroidism or central hypoadrenalism, injection-site lipoatrophy and rare pancreatitis. Labels contraindicate somatropin in acute critical illness (higher mortality in two placebo-controlled trials), active malignancy, severe diabetic retinopathy, closed epiphyses when used for growth, and in Prader-Willi children with severe obesity or respiratory compromise after reported deaths. The safety score of 4 reflects a long human record with real but manageable, well-documented risks; it does not extend to unlabeled products of unknown potency. Research-use framing applies to anything sold outside a pharmacy — this is a prescription biologic and a WADA class-S2 prohibited substance.
Reported side effects
Reported in published literature and user reports. Not a complete list, and not medical advice.
- Fluid retention — peripheral swelling, joint pain, extremity pain, paresthesia, stiffness, myalgia (most common in adults per the Genotropin label)
- Carpal-tunnel-type symptoms secondary to fluid retention (Serostim and Humatrope labels)
- Impaired glucose tolerance / new-onset type 2 diabetes
- Intracranial hypertension (headache, visual changes, nausea) — usually in the first 8 weeks
- Injection-site reactions, rash, lipoatrophy
- Hypothyroidism and unmasked central hypoadrenalism
- In children: slipped capital femoral epiphysis, scoliosis progression
- Pancreatitis (rare)
If severe or unexpected symptoms occur, contact a qualified medical professional. Peptides·Index does not provide medical advice.
Cautions discuss with a clinician
- Acute critical illness after open-heart or abdominal surgery, multiple trauma or acute respiratory failure — increased mortality in two placebo-controlled trials of high-dose somatropin (label)
- Active malignancy — GH stimulates IGF-1 and cell growth; any pre-existing malignancy should be inactive and treatment complete before starting (label)
- Prader-Willi syndrome with severe obesity, history of upper-airway obstruction or sleep apnea, or severe respiratory impairment — fatalities reported (label)
- Active proliferative or severe non-proliferative diabetic retinopathy (label)
- Closed epiphyses in children treated for growth promotion (label)
- Known hypersensitivity to somatropin or excipients, including benzyl alcohol or metacresol in some diluents (label)
- GlucocorticoidsSomatropin inhibits 11β-HSD-1 and can unmask central hypoadrenalism; patients on replacement may need higher doses, while pharmacologic glucocorticoid doses blunt GH's growth effect in children (label)
- CYP450-metabolised drugs (corticosteroids, sex steroids, anticonvulsants, cyclosporine)GH increases CYP450-mediated clearance in humans, so exposure to these drugs may fall; formal studies not done (label)
- Oral estrogenWomen on oral estrogen may need a larger somatropin dose to reach the IGF-1 target (label)
- Insulin and other antidiabetic drugsGH is anti-insulin; antidiabetic doses may need adjustment when somatropin is started (label)
Timeline commonly reported
- Weeks 1–8
The label's early adverse reactions cluster here — fluid-retention symptoms (swelling, joint and limb pain, paresthesia) in adults, and intracranial hypertension when it occurs. Dose titration against IGF-1 is how prescribers manage this; nothing here is a benefit claim.
- Month 6
In the Genotropin adult-GHD trials, lean body mass, total body water and the lean-to-fat ratio rose vs placebo while total body fat and waist circumference fell; bone mineral density transiently declined at 6 months.
- Month 12 and beyond
Bone mineral density returned to baseline by 12 months in the adult trials. In children, height velocity over the first year is the efficacy measure; treatment runs for years under specialist monitoring.
FAQ
Is HGH FDA-approved, and for what?
Yes — as somatropin, a prescription biologic. Labeled uses are pediatric growth failure from GH deficiency, Prader-Willi syndrome, Turner syndrome, idiopathic short stature, SHOX deficiency and small-for-gestational-age short stature, adult GH deficiency, and (Serostim) HIV-associated wasting. Anti-aging, fat loss and athletic use are not approved indications.
Is human growth hormone a peptide?
Technically a protein hormone: a single 191-amino-acid chain of about 22 kDa with two disulfide bridges, far larger than the short synthetic peptides most research vendors sell. It is produced recombinantly in E. coli and is identical in sequence to pituitary GH.
How do IU and mg relate for HGH?
Labels state the cartridge strengths both ways — Humatrope lists 6 mg as 18 IU, 12 mg as 36 IU and 24 mg as 72 IU, i.e. 3 IU per mg. A grey-market '10 IU vial' therefore corresponds to about 3.3 mg of somatropin, assuming the label is honest; purity is not something the IU figure can tell you.
How is HGH supplied and reconstituted?
As a lyophilised powder that is reconstituted before subcutaneous injection. Pharmaceutical presentations include Genotropin two-chamber cartridges (5 mg and 12 mg) and MiniQuicks (0.2–2 mg), Humatrope cartridges (6, 12 and 24 mg with a ~3 mL metacresol-preserved diluent), Zomacton vials (5 mg with 5 mL bacteriostatic saline; 10 mg with 1 mL bacteriostatic water) and Serostim vials (4, 5 and 6 mg; 0.5–1 mL of bacteriostatic or sterile water). Grey-market kits are usually 10 IU vials. This describes the products, not how anyone should use them.
What is the half-life of HGH?
Short: about 3 hours after a subcutaneous dose in GH-deficient adults (Genotropin label), with other brand labels reporting 2.3–4.0 h, and about 0.4 h intravenously. Daily injection is standard because of this; long-acting pegylated or albumin-binding analogues (somapacitan, lonapegsomatropin, somatrogon) were developed to allow weekly dosing.
Is HGH banned in sport?
Yes. Growth hormone, its analogues and fragments sit in WADA class S2 and are prohibited at all times, in and out of competition.
How is HGH different from sermorelin, ipamorelin or CJC-1295?
Those are secretagogues — GHRH analogues or ghrelin-receptor agonists that stimulate the pituitary to release its own GH, so output is capped by the gland's reserve. Somatropin is the hormone itself, so exposure is set by the dose. Only somatropin is an approved drug with a defined human safety record; the secretagogues (apart from tesamorelin) are investigational or research-only.
What are the main safety concerns?
Fluid retention and joint pain, glucose intolerance and diabetes, intracranial hypertension, and the theoretical concern that GH/IGF-1 may promote tumour growth — labels contraindicate it in active malignancy and in acutely critically ill patients, where mortality was higher in trials. Children with Prader-Willi syndrome who are severely obese or have respiratory impairment are also excluded after fatalities.
Sources
Starting references for the library summary. These are not dosing instructions or medical advice.
For research-use educational context only. Not medical advice and not a recommendation to use any compound. Consult a qualified healthcare professional before any health decision.